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Current knowledge and research perspectives on the top ranking causes of mortality
worldwide, i.e., ischemic heart disease and cerebrovascular diseases have developed
rapidly. In fact, until recently, the evidence describing the incidence of acute myocardial
infarction, the underlying risk factors, and the clinical outcomes of those who have
this acute ischemic coronary event has largely been based on studies conducted in
developed countries, with limited data for women and usually of low-ethnic diversity.
Recent reports by the WHO have provided striking public health information, i.e., the
global burden of cardiovascular mortality for the next decades is expected to pre-
dominantly occur among developing countries. Therefore, multiethnic population-based
research including prospective cohorts and, when appropriate, case–control studies, is
warranted. These studies should be specifically designed to ascertain key public health
measures, such as geographic variations in non-communicable diseases, diagnosis of
traditional and potential newly discovered risk factors, causes of death and disability,
and gaps for improvement in healthcare prevention (both primary and secondary) and
specific treatments. As an example, a multinational, multiethnic population-based cohort
study is the Prospective Urban and Rural Epidemiology study, which is the largest
global initiative of nearly 200,000 adults aged 35–70 years, looking at environmental,
societal, and biological influences on obesity and chronic health conditions, such as
ischemic heart disease, stroke, and cancer among urban and rural communities in
low-, middle-, and high-income countries, with national, community, household, and
individual-level data. Implementation of population-based strategies is crucial to optimiz-
ing limited health system resources while improving care and cardiovascular morbidity
and mortality.
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Globally,myocardial infarction is an important cause of premature death. Among itswell-established
modifiable risk factors are hypertension, dyslipidemia, smoking, and diabetes. However, the evi-
dence describing the incidence of acute myocardial infarction, the underlying risk factors, and the
clinical outcomes of those who have this acute ischemic coronary event has largely been based
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on studies conducted in developed countries, with limited data
for women and usually of low-ethnic diversity. Therefore, gen-
eralizability to allow for public health implementation has not
been properly feasible or has been made with high level of
uncertainty (1).
We herein describe recent progress in the research-based
knowledge through well-designed community-based cohorts and
large case–control studies, widely conducted, i.e., including dif-
ferent geographic regions and diverse cultures, languages, income
levels, and ethnicities. This research strategy obviously enhances
external validity or broader generalizability of assessment of risk
factors for acute myocardial infarction and stroke, thus enabling
healthcare providers with reliable foundation to implement cost-
effective prevention strategies on both community and population
levels.
In order to address this paucity of precision and external valid-
ity, high-quality data from well-conducted studies over the last
decade have provided cardiovascular field with clinically relevant
information as well as additional insights on the risk factors asso-
ciated with higher risk for the first myocardial infarction or stroke
(2, 3). Those studies were designed to address the lack of represen-
tativeness of low-income countries and societal minorities as well
as to evaluate the actual impact of traditional and emerging risk
factors on the population attributable risk (PAR), i.e., variation
in prevalence of a risk factor leads to different impact on specific
population risk related to that particular factor.
The INTERHEART study was a multicenter, international,
case–control study, designed to assess the importance of simple
and easily identifiable risk factors for the occurrence of the first
myocardial infarction worldwide (2). Between February/1999 and
March/2003, 15,152 cases and 14,820 controls were enrolled in
262 centers from 52 countries in 7 major geographic regions
of all continents. The most relevant finding was the determina-
tion of 9 risk factors that accounted for over 90% of the PAR
of the first acute myocardial infarction. Moreover, those factors
were easily measured and collected by standardized electronic
data capture forms, and were considered potentially modifiable,
which included the following by decreasing odds ratio: raised
ApoB/ApoA1 ratio (3.25), current smoking status (2.87), psy-
chosocial factors (2.67), diabetes (2.37), history of hypertension
(1.91), abdominal obesity (1.12), alcohol consumption (0.91), reg-
ular physical activity (0.86), and daily consumption of fruits and
vegetables (0.70), indeed all factors being significantly associated
with acute myocardial infarction (p< 0.0001 for all risk factors
and p= 0.03 for alcohol). Furthermore, the associations observed
between these risk factors and acute myocardial infarction were
consistent in both genders and across different ethnicities and
geographic regions, enhancing the worldwide generalizability of
the results.
Similarly, the INTERSTROKE pilot study (3) was also a large
standardized case–control study in 22 countries globally, between
March 1, 2007, and April 23, 2010, which was thought and con-
ducted with the primary objective of evaluating the association
of known as well as newly emerging risk factors with occurrence
of the first stroke and its subtypes. In addition, the investiga-
tors aimed to assess individual contribution of specific risk fac-
tors to the stroke burden while exploring differences between
risk factors for stroke and those for myocardial infarction. In
the first 3,000 cases, 78% with ischemic stroke and 22% with
intracerebral hemorrhagic stroke, and age- and gender-matched
3,000 controls, significant multivariable model-adjusted risk fac-
tors for all cases of stroke included history of hypertension,
current smoking status relative to former or never, abdomi-
nal obesity measured by waist-to-hip ratio, ApoB/ApoA1 ratio,
estimated unhealthy diet risk score, diabetes mellitus, alcohol
intake, psychosocial stress and depression, lack of regular phys-
ical activity, and cardiac causes, which collectively accounted
for nearly 90% (99% CI 82.3–92.2) of the PAR for strokes.
These risk factors were significant for ischemic stroke, whereas
smoking, alcohol intake, diet, hypertension, and waist-to-hip
ratio were significantly associated with intracerebral hemorrhagic
stroke.
Furthermore, the large INTERSTROKE study was recently
presented at the World Congress of Cardiology 2014 Scien-
tific Sessions, yet to be published (4). This second phase of
the case–control study for stroke enrolled more than 27,011
individuals, including 13,604 with stroke and 13,407 age- and
gender-matched controls. Patients were recruited from centers
in North America; Western, Central, and Northern Europe; the
Middle East; South America; China, South and Southeast Asia;
and Africa. As expected, although still preliminary, the newly
released results are concordant to those of the first phase of the
INTERSTROKE abovementioned. The authors have identified
a number of modifiable risk factors that explain approximately
90% of the PAR for stroke, with hypertension being the most
important one. The other risk factors that contribute most to the
stroke risk include lipid levels, physical inactivity, smoking, and
diet. In addition, larger waist-to-hip ratios, a history of diabetes,
increased alcohol intake, psychosocial stress and/or depression,
and cardiac causes all contribute to risk for developing a first
stroke.
Moreover, recent reports by the World Health Organiza-
tion have provided striking public health information, i.e., the
global burden of cardiovascular mortality for the next decades
is expected to predominantly occur among developing countries.
Current statistics of premature deaths due to cardiovascular
diseases (CVD) ranges from 4% in high-income countries to
astonishing estimate of 80% of the total CVD mortality occur
in developing countries. This imbalance obviously leads to
growing inequalities in the occurrence, outcomes, and heath
care related costs of CVD across various income levels and
populations (5).
Therefore, multiethnic population-based research including
prospective cohorts and, when appropriate, case–control and
cross-sectional studies, is warranted. Epidemiological and clinical
studies should be specifically designed to ascertain key public
health measures, such as geographic variations, in the preva-
lence and incidence of non-communicable diseases, diagnosis of
traditional and potential newly discovered risk factors, causes
of death and disability, and practice gaps. The pooled data will
provide the rationale for proposals and implementation of feasible
strategies, with primary goals of improvement in cardiovascu-
lar disease prevention, both primary – starting early in life or
even during fetal development – and secondary, with sustained
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long-term accessibility, affordability, and patient adherence to
available effective medications, and adoption of quality of care
improvement programs.
Finally, current epidemiological research recognizes the contin-
uous need for global, accurate, and reliable description of mor-
bidity and mortality due to cardiovascular causes, which would
enable comparisons while assessing the progress of delivery of
benefit-proven cardiovascular care (6, 7).
As a good example of research with warranted broader
geographic and ethnic representativeness, the multinational,
population-based cohort ProspectiveUrban andRural Epidemiol-
ogy (PURE) study is the largest global initiative assessing societal,
biological, and environmental influences on relevant chronic pub-
lic health conditions, such as ischemic heart disease and stroke
(8). The PURE study currently comprises nearly 200,000 adults
aged 35–70 years who were initially enrolled between 2003 and
2009, from either urban or rural communities in low-, middle-,
and high-income countries. Prespecified statistical assumptions
were taken into consideration to collect huge amount of rel-
evant data at national, community, household, and individual
levels, since the baseline and throughout the long-term follow-up.
Some of its recent contributions include the following: contem-
porary data on hypertension awareness, treatment, and control
(9), i.e., in a large multinational population sample, 46.5% of
participants with hypertension were aware of the diagnosis and
blood pressure control was found in 32.5% of those receiving
antihypertensive medications. Overall, those findings emphasize
the substantial gap that requires improvement efforts by pub-
lic health polices in terms of adequate hypertension diagno-
sis, broad accessibility to inexpensive treatments, and eventu-
ally targeted blood pressure control and lower morbidity and
mortality.
In terms of non-pharmacological prevention strategies, among
a sample of patients with prior coronary heart disease or cere-
brovascular disease event from countries with various income
levels, the proportion of individuals adopting all three healthy
lifestyle behaviors, i.e., avoidance or complete smoking cessa-
tion, eating a healthy diet with regular, daily consumption of
vegetables and fruits, and undertaking physical activities was
only 4.3% (95% CI, 3.1–5.8%), with individuals from higher
income countries being more likely to report a healthy behav-
ior (10). Lastly, because sustained use of secondary prevention
medications is not ideally offered worldwide – especially low in
poorer countries and in rural-resident individuals – systematic,
regionally customized feasible approaches are needed to improve
the long-term use of simple, affordable and effective treatments,
i.e., antiplatelets, betablockers, angiotensin-converting-enzyme
inhibitors or angiotensin-receptor blockers, and statins in individ-
uals with a history of coronary heart disease, stroke, or peripheral
artery disease (11).
After taking this knowledge into consideration, what would
be the next steps for prevention of myocardial infarction, stroke,
heart failure, and related deaths? In order to achieve that goal
of prevention while targeting significant reductions in mor-
bidity and mortality, continuously growing body of evidence
through population-based research and, consequently, worldwide
implementation of simple and efficient large-scale primary and
secondary prevention strategies are highly demanded and, there-
fore, should be a global priority on a multilevel organized task
force.
Indeed, it is important to discuss how to apply newly developed
evidence into daily practice, which certainly requires huge collab-
oration on global, political, governmental, societal, professional,
and local levels to foster rapid, full, and measurable implementa-
tion of simple, widely available, cost-effective, and safe strategies
of prevention and treatment targeting significant reductions in
cardiovascular mortality. As recently proposed by the 25 25
World Heart Federation Program, the Global Cardiovascular Dis-
easeTaskforce calls on theCVDcommunity to endorse, build local
capacity with financial and human resources, and promptly make
strong efforts on four key targets, i.e., fight against lack of regular
physical activity, implementation of massive health polices for
hypertension/blood pressure management, governmental policies
for the reduction in dietary salt intake as well as tobacco taxation
control and consumption cessation programs. By acting on a
global perspective, we expect to achieve the feasible goal of 25%
relative reduction in premature cardiovascular disease mortality
by 2025 (12).
Furthermore, some recommendations have been recently
released to provide guidance to improving cardiovascular health at
the community level, which include some interventions for public
health programs: broad surveillance, which is intended to guar-
antee that every person in all communities should have access to
clear information about the public health impact of ischemic heart
disease and cerebrovascular disease, i.e., the top ranking causes
of death and disease-related disability and poor quality of life;
general and specific health education and large-scale media; orga-
nizations and partnerships built at the community level; ensuring
personal health services; environmental change and finally, policy
change (13).
TheWHF 25 25 Prevention Program expected risk reduction
is in alignment with the WHO “Global Action Plan for the Pre-
vention andControl ofNon-CommunicableDiseases 2013–2020,”
which was endorsed by the World Health Assembly in May 2013.
The WHO primary goal is a 25% relative reduction in the inci-
dence of premature mortality due to non-communicable diseases,
including CVD. It is relevant to mention some of the main princi-
ples of this global prevention plan: lifespan intervention approach,
which makes sense in terms of prevention by avoidance of long
exposure to risk factors as well as to the causes of the risk factors;
organization, autonomy, continuing education and training, and
required financial resources at the community and individual lev-
els; rapid and sustained use of evidence-based strategies; universal
health coverage; multiprofessional and multisectoral actions (14).
Therefore, healthcare providers, physicians, non-physicians,
cardiovascular associations, and eventually governments/policy
makers should adopt the current platform and perspectives,
thought as being the scientific foundation, for continuous assess-
ment of CVD burden as well as proposals and implementation of
population-based strategies aimed at reducing morbidity, mortal-
ity, and healthcare costs, thus optimizing limited health system
resources while improving care and clinical outcomes.
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